Aging Clinical and Experimental Research

, Volume 15, Issue 2, pp 89–98

Preventing osteoporotic fractures with bisphosphonates: A review of the efficacy and tolerability

Review Article

DOI: 10.1007/BF03324485

Cite this article as:
Masud, T. & Giannini, S. Aging Clin Exp Res (2003) 15: 89. doi:10.1007/BF03324485

Abstract

Although change in bone mineral density was the outcome most commonly measured in early clinical trials of osteoporosis therapies, it is now understood that the most clinically important outcome is reduction in the risk of fractures. Of currently available osteoporosis therapies, the bisphosphonates have been most thoroughly investigated in studies with fracture risk as the primary outcome. The most widely studied bisphosphonates include etidronate, alendronate and risedronate. Alendronate and risedronate have the most compelling evidence for vertebral and non-vertebral fracture reduction. This review provides a comprehensive overview of the anti-fracture efficacy of bisphosphonates at the spine, hip, and non-vertebral sites.

Key words

Bisphosphonatesfractureosteoporosispostmenopausal womentolerability

Copyright information

© Springer Internal Publishing Switzerland 2003

Authors and Affiliations

  1. 1.Clinical Gerontology Research Unit and Department of MedicineCity HospitalNottinghamUK
  2. 2.Department of Medical and Surgical Sciences, Clinica Medica IUniversity of PadovaPadovaItaly